Share Twitter LinkedIn Facebook Email Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Intermediate/Poor And Favorable Risk RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO Kidney 4 Mins Read
Impact of Latino Ethnicity on Gut Microbiome in mRCC: ASCO 2024 Study – Regina Barragan-Carillo, Phd – City of Hope ASCO Annual Meeting 2 Mins Read